Rhythm Pharmaceuticals
RYTM
80 hedge funds and large institutions have $621M invested in Rhythm Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 21 reducing their positions, and 23 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 21
3.85% less ownership
Funds ownership: 96.47% → 92.62% (-3.8%)
10% less funds holding
Funds holding: 89 → 80 (-9)
35% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 23
36% less capital invested
Capital invested by funds: $973M → $621M (-$352M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
95% less call options, than puts
Call options by funds: $1K | Put options by funds: $19K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$25.9M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$4.95M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$2.78M |
| 4 |
Aviva
London,
United Kingdom
|
+$2.37M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$22.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$19.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.7M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.54M |
RYTM Hedge Fund Activity: Q1 2020 in Review
80 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2020, worth a combined $621M — down 36% from $973M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of RYTM and 15 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 28 added.
The largest buyer was Primecap Management, adding an estimated $25.9M. The largest seller was Deerfield Management, cutting an estimated $22.5M.
- 80 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2020, down from 89 in Q4 2019.
- Funds reported $621M of Rhythm Pharmaceuticals stock for Q1 2020, down 36% quarter-over-quarter.
- 15 funds opened new Rhythm Pharmaceuticals positions in Q1 2020 and 23 closed out, a net change of -8 holders.
- The largest Rhythm Pharmaceuticals buyer in Q1 2020 was Primecap Management, an estimated $25.9M added.
- The largest Rhythm Pharmaceuticals seller in Q1 2020 was Deerfield Management, an estimated $22.5M sold.
Based on aggregated 13F filings for Q1 2020.